Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
COVID-19 variant mRNA vaccine
- Development stage
- Preclinical
- Lead developer
- RpexBio
- Modality
- mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
The COVID-19 variant mRNA vaccine is an investigational messenger RNA-based vaccine developed by RpexBio for the prevention of COVID-19 caused by variant strains of the SARS-CoV-2 virus. The vaccine utilizes mRNA technology to deliver the genetic sequence encoding the SARS-CoV-2 spike antigen into host cells, where it is translated to elicit a protective immune response, including the production of neutralizing antibodies and T-cell activation. The program is currently in the IND-enabling phase, with an Investigational New Drug (IND) filing planned for 2025.
- Other names
- 생니어리 19색 변이주 mRNA 백신
02
Targets
Host ribosomes and translation initiation machinerySARS-CoV-2 spike
Beyond the preview
Go deeper on COVID-19 variant mRNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on COVID-19 variant mRNA vaccine.